Preoperative anti-TNF and anastomotic leak in ileocecal resection

What is known

• In 815 CD patients undergoing ileocolic resection, preoperative anti-TNF, vedolizumab, or ustekinumab was not significantly associated with 90-day intra-abdominal septic complication; leak rate overall was 3.2%. ¹
• Hypoalbuminaemia (albumin <3.5 g/dl), not biologic exposure, was the independent risk factor for septic complications; authors conclude biologics should not delay surgery. ¹
• A narrative review notes some studies reported increased infectious complications with preoperative anti-TNF, but the largest prospective study found no deleterious effect. ²

What is unknown / caveats

• Earlier studies reported increased infectious complications with preoperative anti-TNF; the largest prospective data found no such effect ²
• Retrieved studies assessed leak/septic complications as harm, not benefit. None tested anti-TNF as a protective factor against leak
• Primary evidence is retrospective cohort with composite septic endpoints, not leak-specific RCTs
• No retrieved study frames or supports a leak-reducing benefit of preoperative anti-TNF.

References

1. [No authors listed]. Hypoalbuminaemia, Not Biologic Exposure, Is Associated with Postoperative Complications in Crohn's Disease Patients Undergoing Ileocolic Resection. J Crohns Colitis. 2021;15(7):1142-1151. PMID: 33388775.

2. [No authors listed]. Perioperative management of ileocecal Crohn's disease in the current era. Expert Rev Gastroenterol Hepatol. 2020;14(9):843-855. PMID: 32729736.

For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.

Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct.